Interpretation of research progress on EGFR-mutant non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- VernacularTitle:2025年美国临床肿瘤学会（ASCO）会议EGFR突变型非小细胞肺癌研究进展解读
- Author:
Xuxu ZHANG
1
,
2
;
Jiahe LI
1
,
2
;
Jipeng ZHANG
2
;
Wei LI
2
;
Wen LIU
2
;
Bo BAO
2
;
Qiang LU
2
Author Information
1. Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China
2. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, 710038, P. R. China
- Publication Type:Journal Article
- Keywords:
EGFR-mutant;
non-small cell lung cancer;
immune therapy;
targeted therapy;
interpretation;
2025 ASCO Annual Meeting
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(01):19-29
- CountryChina
- Language:Chinese
-
Abstract:
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. At the meeting, researches on the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) once again took the spotlight. Combination therapy strategies have demonstrated the potential to overcome resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) and prolong survival. Meanwhile, progress has also been made in individualized treatment strategies for young patients and those with fibrotic interstitial lung disease. However, the complexity of resistance mechanisms, special treatment considerations for different populations, and the impact of socioeconomic factors on treatment accessibility remain challenges in the field of EGFR-mutant NSCLC treatment. In the future, it is necessary to further explore more effective treatment regimens and expand the accessibility of precision medicine to maximize patient benefits.
